Justin Schreiber Sells 25,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the sale, the chief executive officer now directly owns 2,703,715 shares in the company, valued at approximately $14,032,280.85. This represents a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The shares were sold at an average price of $6.52, for a total transaction of $163,000.00.

LifeMD Stock Performance

LFMD opened at $5.78 on Tuesday. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. The company’s fifty day moving average price is $5.53 and its two-hundred day moving average price is $5.57. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $12.88. The company has a market cap of $250.34 million, a price-to-earnings ratio of -9.03 and a beta of 1.49.

Analyst Upgrades and Downgrades

LFMD has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. Lake Street Capital assumed coverage on shares of LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. Finally, Mizuho assumed coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.57.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State Street Corp raised its holdings in shares of LifeMD by 20.0% in the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after purchasing an additional 192,861 shares during the last quarter. Royce & Associates LP raised its holdings in shares of LifeMD by 14.6% in the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock valued at $4,721,000 after purchasing an additional 114,710 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of LifeMD by 852.6% in the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after purchasing an additional 108,822 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of LifeMD by 63.6% in the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of LifeMD by 11.4% in the third quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock valued at $4,293,000 after purchasing an additional 83,598 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.